The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Ezetimibe therapy: mechanism of action and clinical update
|
|---|---|
| Published in |
Vascular Health and Risk Management, July 2012
|
| DOI | 10.2147/vhrm.s33664 |
| Pubmed ID | |
| Authors |
Binh An P Phan, Thomas D Dayspring, Peter P Toth |
| Abstract |
The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 18% |
| Japan | 1 | 6% |
| Unknown | 13 | 76% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 47% |
| Practitioners (doctors, other healthcare professionals) | 6 | 35% |
| Scientists | 3 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 459 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| United States | 1 | <1% |
| China | 1 | <1% |
| Unknown | 456 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 94 | 20% |
| Student > Ph. D. Student | 41 | 9% |
| Student > Master | 40 | 9% |
| Researcher | 35 | 8% |
| Other | 28 | 6% |
| Other | 75 | 16% |
| Unknown | 146 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 95 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 55 | 12% |
| Biochemistry, Genetics and Molecular Biology | 53 | 12% |
| Agricultural and Biological Sciences | 40 | 9% |
| Chemistry | 15 | 3% |
| Other | 39 | 8% |
| Unknown | 162 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2023.
All research outputs
#2,812,255
of 25,996,988 outputs
Outputs from Vascular Health and Risk Management
#84
of 813 outputs
Outputs of similar age
#17,241
of 177,539 outputs
Outputs of similar age from Vascular Health and Risk Management
#2
of 16 outputs
Altmetric has tracked 25,996,988 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 813 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,539 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.